TESTIM Drug Patent Profile

When do Testim patents expire, and what generic alternatives are available?

Testim is a drug marketed by Endo Operations and is included in one NDA.

The generic ingredient in TESTIM is testosterone. There are sixty-nine drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Testim

A generic version of TESTIM was approved as testosterone by ACTAVIS LABS UT INC on January 27^th, 2006.

Summary for TESTIM

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	16
Patent Applications:	4,388
Drug Prices:	Drug price information for TESTIM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TESTIM
What excipients (inactive ingredients) are in TESTIM?	TESTIM excipients list
DailyMed Link:	TESTIM at DailyMed

See drug prices for TESTIM

See drug sales revenues for TESTIM

Recent Clinical Trials for TESTIM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Endo Pharmaceuticals	Phase 4
Instituto de Investigacion Sanitaria La Fe	Phase 3
Marianne Andersen	Phase 4

See all TESTIM clinical trials

Pharmacology for TESTIM

Drug Class	Androgen
Mechanism of Action	Androgen Receptor Agonists

Paragraph IV (Patent) Challenges for TESTIM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TESTIM	Gel	testosterone	1%	021454	1	2008-08-21

US Patents and Regulatory Information for TESTIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002	AB2	RX	Yes	Yes

Expired US Patents for TESTIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002
Endo Operations	TESTIM	testosterone	GEL;TRANSDERMAL	021454-001	Oct 31, 2002

EU/EMA Drug Approvals for TESTIM

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Warner Chilcott UK Ltd.	Intrinsa	testosterone	EMEA/H/C/000634Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28
Warner Chilcott  Deutschland GmbH	Livensa	testosterone	EMEA/H/C/000630Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28

International Patents for TESTIM

See the table below for patents covering TESTIM around the world.

Country	Patent Number	Title	Estimated Expiration
Egypt	24882	Testosterone gel/macrocyclic enhancer
Norway	873145
Iceland	2667
Japan	S63501954
Germany	60315939
Canada	2470200	COMPOSITION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)
Lithuania	5235	FARMACINĖ KOMPOZICIJA (PHARMACEUTICAL COMPOSITION)

Supplementary Protection Certificates for TESTIM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
8703473	91289	Luxembourg		PRODUCT NAME: TESTIM; REGISRATION NO 1768/92

Market Dynamics and Financial Trajectory for TESTIM

Last updated: February 19, 2026

What is TESTIM?

TESTIM (tremelimumab) is an anti-CTLA-4 monoclonal antibody developed by Immutep for oncology indications. It is part of immune checkpoint inhibitor class drugs, designed to enhance T-cell activation by blocking inhibitory pathways.

Current Development Status and Approvals

Status	Details
Clinical Trials	Phase 2/3 trials in multiple cancers including mesothelioma, non-small cell lung cancer (NSCLC), and melanoma.
Regulatory Approvals	Not yet approved for any indication globally.
Licensing Agreements	Partners include AstraZeneca (trial integrations) and others exploring combination therapies.

Market Size and Competitive Landscape

Oncology Market

The global oncology drug market is valued at approximately $182 billion in 2022, projected to reach $315 billion by 2028, with a CAGR of roughly 8.5% (IQVIA, 2022). Immune checkpoint inhibitors constitute a significant share, currently estimated at 50%.

Key Competitors

• Ipilimumab (Yervoy): Approved for melanoma, $3.7 billion in global sales in 2021.
• Nivolumab (Opdivo): $8.4 billion in 2021 sales.
• Pembrolizumab (Keytruda): Leading PD-1 inhibitor, $14.4 billion in 2021 sales.

TESTIM operates within this class but remains in clinical development; no recent FDA or EMA marketing authorization.

Market Challenges

• High competition among existing drugs with established efficacy.
• Uncertain clinical trial outcomes; drug approval depends on demonstrating superior safety or efficacy.
• Pricing pressures from healthcare payers.

Financial Projections and Investment Considerations

Revenue Potential

• Based on comparable drugs, peak annual sales may reach $1–3 billion if approved for multiple indications.
• Market penetration assumes successful trial outcomes, regulatory approval, and strategic licensing.

Cost Structure

• Clinical trial costs: Estimated at $50–$100 million annually, depending on trial scope and phase.
• R&D expenses: High; cost of developing immunotherapies remains substantial due to trial complexity.

Investment Risks

• Trial failures or regulatory setbacks.
• Competition from proven therapies, especially in combination regimens.
• Potential delays in trial recruitment or data readouts.

Funding and Partnerships

• Immutep and partners have secured over $250 million in funding for early-stage trials.
• Strategic alliances with pharma companies aim to accelerate development and commercialization.

Regulatory Trends and Policy Impact

• Accelerated approval pathways for promising immunotherapies in oncology.
• Increasing reimbursement pressures may limit pricing and impact revenue growth.
• Evolving biomarker requirements could influence trial design and approval timelines.

Key Market Opportunities

• Combination therapy development with PD-1/PD-L1 inhibitors.
• Expansion into tumor types with unmet medical needs such as mesothelioma.
• Biomarker-driven patient selection to improve trial success and market adoption.

Summary

TESTIM remains in the pipeline with an uncertain timeline to market. Its financial trajectory hinges on successful clinical outcomes, regulatory approval, and market adoption strategies. The competitive oncology immunotherapy space presents significant barriers, but successful positioning in niche indications could yield lucrative opportunities.

Key Takeaways

• TESTIM is an investigational immunotherapy with potential to enter a rapidly growing oncology market.
• Market size for immune checkpoint inhibitors exceeds $180 billion, with competitive pressures intensifying.
• Financial success depends on trial results, approval timing, and strategic licensing.
• Development costs are high; risks include clinical failures and market entry delays.
• Strategic combination therapies and biomarker strategies can influence market penetration and revenues.

Frequently Asked Questions

1. When could TESTIM receive regulatory approval?

Approval depends on clinical trial outcomes. If phase 2/3 trials demonstrate safety and efficacy, submissions could occur within 2–3 years, with potential approval within 1–2 years post-submission.

2. What are the main competitors for TESTIM?

Ipilimumab, nivolumab, and pembrolizumab are leading competitors with established markets. TESTIM differentiates through combination approaches or specific indications, but faces significant market entry barriers.

3. How much revenue could TESTIM generate?

If approved and successfully marketed, peak annual sales might reach $1–3 billion, contingent on indications, market penetration, and pricing.

4. What are the main risks involved in investing in TESTIM development?

Key risks include unsuccessful trial results, regulatory setbacks, competition, and market pricing pressures.

5. How do regulatory policies influence TESTIM’s prospects?

Fast-track approvals and orphan drug designations may accelerate timeline to market, but reimbursement policies and biomarker requirements could delay or restrict market access.

---

References

1. IQVIA. (2022). Global Oncology Market Report. Retrieved from https://www.iqvia.com
2. Immutep. (2023). Corporate Presentation. Retrieved from https://www.immutep.com
3. FDA. (2022). Breakthrough Therapy Designation. Retrieved from https://www.fda.gov